BeiGene settles BRUKINSA patent litigation; generic entry no earlier than June 15, 2037

BeOne Medicines Ltd.

Settlement with MSN allows generic BRUKINSA in U.S. no earlier than June 15, 2037, subject to customary accelerations.
Composition of matter patent expiring April 2034 was not challenged by MSN in the litigation.
Patent litigation against Sandoz also dismissed; all ANDA suits for BRUKINSA now resolved.
Parties filed joint stipulation to dismiss; settlement submitted to FTC and DOJ for review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.